[Yu Jin-hee, Edaily Reporter] As the domestic stock market has recently entered a lull centered on semiconductors and key Information Technology (IT) stocks, investment sentiment is rapidly shifting back to the pharmaceutical and biotech sectors. In particular, a preference for “medium-risk, high-return” investments is becoming evident, centered on small- and mid-cap stocks that have demonstrated clear momentum—such as top management’s strong commitment to supporting the stock price, differentiated core technology, and proven financial turnarounds. On the 30th, three pharmaceutical and biotech companies made a strong entry into the list of the top 15 gainers across the entire domestic stock market, clearly demonstrating this shift in market dynamics.

KM Pharmaceutical: Top Management Pledges 1 Billion KRW of Personal Funds to Address Extreme Undervaluation at a PBR of 0.2x

According to KG Zeroin MP DOCTOR, KM Pharmaceutical, Lemon Healthcare, and JW SHINYAK were among the “Top 15” stock price gainers in the domestic stock market on the 30th, demonstrating the strong potential of these three pharmaceutical and biotech companies. KM Pharmaceutical surged 30.00% compared to the previous trading day (closing at 1,755 KRW), hitting the daily upper limit. Lemon Healthcare also spiked 29.85% (closing at 5,350 KRW) to reach the upper limit. JW SHINYAK ended the trading session on a strong upward trend, rising 15.57% (closing at 1,811 KRW).

The primary driving force behind KM Pharmaceutical hitting the upper limit stems from its top executive’s commitment to responsible management and comprehensive shareholder-friendly policies. KM Pharmaceutical took decisive action to overcome the negative impact of being designated as a company under administrative review on KOSDAQ due to insufficient market capitalization and to restore its corporate value.

Baek Seung-won, CEO of KM Pharmaceutical, personally contributed approximately 1 billion KRW from his own funds to participate in a third-party private placement, and the company completed the payment without delay on the 24th. In addition, the company announced a decision to repurchase 300 million KRW worth of treasury stock (equivalent to 3.72% of total issued shares), demonstrating a strong commitment to stabilizing the stock price. Chairman Kang Il-mo, the largest shareholder, also continued to purchase shares on the open market, raising the combined stake held by the largest shareholder and related parties to 39.6%. Furthermore, the company implemented various self-help measures, including exploring the sale of its Seoul sales headquarters building to secure funds for improving its financial structure.

On the technology and asset front, the market reassessed the company’s extreme undervaluation—with a price-to-book ratio (PBR) of just 0.27x. Based on its quasi-drug and cosmetics manufacturing technologies, KM Pharmaceutical possesses Good Manufacturing Practice (GMP) production infrastructure and real estate assets capable of in-house manufacturing. Its product lineup includes flagship products such as “Pororo Toothpaste,” infant oral care products, and skin-friendly lotions and bath products made with natural raw materials. The announcement of robust shareholder return policies—amid assessments that its market capitalization was significantly below its asset value—attracted significant demand from value investors.

KM Pharmaceutical is aggressively reorganizing its distribution networks in existing core Asian markets, such as China and Vietnam, by leveraging its strong brand power, while actively pursuing entry into the North American market based on the competitiveness of its proprietary brands. Alongside these efforts, the company plans to restore profitability in its core business by expanding Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) orders.

For KM Pharmaceutical to move beyond a short-term surge in its stock price and establish a long-term upward trajectory, a reliable return to profitability in its core business must accompany the fulfillment of the requirement to resolve administrative issues—namely, maintaining a market capitalization of 20 billion KRW. KM Pharmaceutical recorded consolidated revenue of 15.99 billion KRW last year, achieving 10.5% year-over-year top-line growth, but its operating loss widened to 2.92 billion KRW.

In a recent letter to shareholders, CEO Baek emphasized, “Resolving the administrative issue designation and restoring corporate value are our top management priorities. We will do our utmost to regain market trust and maximize corporate value through responsible management and continuous shareholder-friendly policies.”

Lemon Healthcare: 120 Million Medical Data Pipeline and the Technical Moat of the LDB Platform

Lemon Healthcare, a mobile healthcare data platform company, hit the daily price limit as the value of its core technology, “Lemon Data Bridge” (LDB)—which received an A/A rating in technology evaluations—aligned with the momentum of its Initial Public Offering (IPO).

Lemon Healthcare’s core competitive advantage lies in LDB, a proprietary platform architecture that organically connects the closed Electronic Medical Record (EMR) and Picture Archiving and Communication System (PACS) systems of large hospitals. Lemon Healthcare defines itself as a real-time, bidirectional medical data relay platform technology company rather than a simple System Integration (SI) firm. LDB technology consists of three core modules: “Lemon Private (PrivateAPI),” which standardizes APIs by service purpose; “QAB (QueryAgentBox),” a standardized connection module that enables real-time data relay even within closed internal hospital network environments; and “F-Flow,” an integrated operational structure that monitors and manages the overall data flow.

This platform is implemented across three solution lineups: Hospital Smart Services (LDB-H), Electronic Documents & Certificates (LDB-E), and Data Relay (LDB-D). Built on a common architecture, it features a Software as a Service (SaaS) structure that allows for immediate deployment to new hospital integrations through account expansion, without the need for separate, complex development. Its real-time connectivity and operational expertise—developed over nearly a decade across more than 130 tertiary and major general hospitals in Korea, including Seoul National University Hospital and Severance Hospital—constitute a formidable technical barrier to entry that cannot be easily replicated in a short period through capital investment alone. Approximately 30 domestic patents and 10 international patents further reinforce this technological moat.

In addition, Lemon Healthcare has accumulated over 120 million high-quality medical data records based on patient consent through its flagship application, “Cheong-guui Sin” (God of Claims). By establishing a pipeline system that stably supplies this standardized, large-scale dataset to AI pharmaceutical and medical IT companies, it has completed a business transformation from a mere medical solution provider into a medical AI data platform enterprise.

Financially, the company is also presenting a turnaround blueprint. Unlike many biotech and healthcare companies pursuing technology-special listings that suffer from chronic losses, Lemon Healthcare has demonstrated a structure capable of generating actual profits. Last year, it significantly reduced its losses, posting revenue of 15.9 billion KRW and an operating loss of 600 million KRW. For this year, it has officially projected its first-ever annual operating profit turnaround since its inception, targeting revenue of 24.1 billion KRW and an operating profit of 6.5 billion KRW.

Lemon Healthcare’s mid- to long-term corporate value hinges on achieving its 6.5 billion KRW operating profit target this year, as well as expanding the proportion of revenue derived from commercialized medical AI data. The recent expansion of simplified indemnity insurance claim systems (Silson24) and the accelerated development of customized medical MyData ecosystems are expected to open up a vast downstream market for Lemon Healthcare.

An official from Lemon Healthcare stated, “The operational experience with the LDB platform and data management expertise accumulated over 10 years through partnerships with 130 major domestic hospitals serve as an entry barrier that cannot be easily breached, even by financial power. This robust barrier of experience will serve as the foundation for maintaining an overwhelming competitive edge against large corporations in the future.”

JW SHINYAK: Organic Fusion of Ethical Drug (ETC) Heritage and Dermacosmetics Brand 'DUCREY'

JW SHINYAK, a KOSDAQ-listed pharmaceutical company under the JW Group, has generated new growth momentum by successfully expanding its presence into the rapidly growing hair loss management dermacosmetics (functional cosmetics) market, leveraging its existing dominant prescription network in clinic-based ethical drugs (ETC).

JW SHINYAK is a pharmaceutical manufacturing and sales company with an established sales network and competitive products in clinic-level markets such as dermatology, urology, pediatrics, and otorhinolaryngology. It has built a stable earnings foundation based on a lineup of both original and generic ethical drugs (ETC), including the antifungal agents “Hitrazole” and “Oneflu Capsule,” and the dermatological treatment “Pidi Tablet.” In the hair loss treatment sector, the company maintains a robust portfolio that includes the finasteride-based “Monad” and “Monasta,” the dutasteride-based “Dutamoa,” and the minoxidil topical formulation “Mydil 5% Foam.” Among these, its flagship product “Monad” serves as a key revenue driver for the company, consistently generating approximately 3 billion KRW in annual revenue on its own.

What sets JW SHINYAK’s core technology and business strategy apart is its ability to proactively anticipate the paradigm shift in the hair loss market and develop an integrated solution that combines “treatment (pharmaceuticals)” and “daily care (dermacosmetics).” JW SHINYAK signed an exclusive distribution agreement with Pierre Fabre, a leading French pharmaceutical company, to exclusively introduce “DUCRAY Neoptide Expert,” a global hair care brand, to the Korean market.

JW SHINYAK is initially supplying this product through its well-established sales networks in dermatology and specialized hair loss clinics, while expanding consumer touchpoints via a two-track strategy that simultaneously operates its official online store alongside both online and offline beauty channels. With hair loss-related products currently accounting for about 10% of total revenue, the addition of this high-margin dermacosmetics lineup is positioning itself as a key driver in enhancing the company’s overall profitability structure.

An official from JW SHINYAK remarked, “The product strength of the DUCRAY brand, which has already been proven in global markets, is generating strong synergies when combined with JW SHINYAK’s robust dermatology clinic sales infrastructure. We will cultivate this integrated hair loss portfolio—combining therapeutics and functional cosmetics—into the core growth pillar of our company’s future.”